Conversely however, a substantial amount of evidence exists indicating that PP2Cδ (PPM1D/Wip1) is an oncogene; it has been shown to inhibit the activity of four different tumor suppressor proteins (p53, ATM, INK4A and ARF), to inhibit the function of the checkpoint kinases Chk1 and Chk2, to negatively affect base-excision repair and to be overexpressed in various different human malignancies, including e.g. breast carcinomas, ovarian carcinomas, neuroblastomas and medulloblastomas [2,4-6]. This evidence concerns the gene TP53 and breast carcinoma.